Gold Standard Diagnostics' Next-Generation Lyme Disease Testing Becoming Widely Accepted Amongst Clinical Laboratories

Published: Jun 19, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics, Corp. (GSD,, a leading manufacturer and marketer of clinical laboratory instrumentation and assays for the in vitro diagnostics market, announces new Line Immunoassay technology for Lyme confirmation testing. GSD gives clinical laboratories an FDA cleared, improved option for serological confirmation testing for Lyme disease according to the CDC-recommended two-step process. Both the IgG and IgM line blots are substantially equivalent to traditional Western Blot technology, but offer advancements in usability and objectivity through use of Line Immunoassay technology. GSD’s LIA test strips offer numerous enhancements including: improved sensitivity and specificity, consistent results, large lot sizes, easier handling and automation options.

Help employers find you! Check out all the jobs and post your resume.

Back to news